Nemolizumab Strikes Again: Galderma’s IL-31 Blocker Shows Long-term Improvements in AD
Recently, U.S. Food and Drug Administration approved for prurigo nodularis (PN), nemolizumab (Nemluvio, Galderma) improved signs and symptoms of atopic dermatitis for more than one year, according to the ARCADIA open-label extension study. Nemolizumab (Nemluvio) specifically inhibits interleukin (IL)-31 cytokine signaling, which is known to drive itch and is involved in inflammation. The new data […]